Beckman Coulter's Access Ostase
This article was originally published in The Gray Sheet
Blood test is the first serum-based assay cleared by FDA as an aid in management of osteoporosis and Paget's disease, Beckman reports April 19. The automated assay can measure bone metabolism three to six months after osteoporosis therapy, while traditional bone densitometry can only measure changes after one to two years of therapy, the firm maintains
You may also be interested in...
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.